Alzheimer’s Association comment on Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
CHICAGO, April 7, 2022 — “We are currently reviewing the CMS final decision. At initial review we are very disappointed ...
